Uric Acid

3

Review clinical trials related to Uric Acid. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

The goal of this clinical trial is to compare the changes in serum urate levels and symptom recurrence after reducing or suspending urate-lowering agents in well-controlled gout patients (the 'after dishes are clean' state in the Dirty Dish hypothesis) Researchers will compare three randomized groups: the reducing group takes febuxostat 20 mg once daily for 12 months, the discontinuing group takes a placebo once daily for 6 months, followed by febuxostat 20 mg once daily for the next 6 months, and the maintaining group continues their pre-study urate-lowering agents for 12 months, serving as an observational reference group. During the 12-month study period, participants will visit every 3 months for laboratory evaluations including serum urate levels, and for checking symptomatic status using questionnaires and diaries. Additionally, musculoskeletal ultrasonography and serum sample collection will be performed at baseline to study predictors for maintaining serum urate levels \<7.0 mg/dL after reducing or suspending urate-lowering therapy.

Participants needed: 59
Trial details
Phase: Phase 4Age: 19-79Biological sex: AllType: InterventionalSponsor: Seoul National University HospitalUpdated: Apr 29, 2026Locations: 1
Eligibility criteria

Adult gout patients aged ≥19 but <80 years. [+5]

Subjects who continuously require prophylactic low-dose colchicine/NSAIDs. [+8]

Status: Recruiting

The Effects of Endotracheal Suctioning on Pain and Serum Markers

The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.

Participants needed: 110
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Loma Linda UniversityUpdated: May 21, 2025Locations: 1
Eligibility criteria

Adults (aged 18 years and older) [+4]

Patients receiving neuromuscular blocking agents [+1]

Status: Recruiting

The Effect of Allopurinol on the Risk of Cardiovascular Events in Patients with Cardiovascular Risk

Numerous studies, but not all, have suggested a positive effect of allopurinol on the cardiovascular system. The ALL-VASCOR study aims to evaluate the efficacy of allopurinol therapy for improving cardiovascular outcomes in patients at high and very high cardiovascular risk, excluding ischemic heart disease. This is particularly important due to the high cost of cardiovascular disease treatment and its status as one of the leading causes of death.

Participants needed: 1,116
Trial details
Phase: Phase 3Age: 40-70Biological sex: AllType: InterventionalSponsor: Poznan University of Medical SciencesUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

Age: between 40-70 years old. [+8]

Taking allopurinol, febuxostat or other hypouricemic drugs. [+10]